Relamorelin

Summary

Relamorelin (CHEMBL4297525) is a phase-3 clinical-stage small molecule.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Clinical trials: 7
• Chemistry: 791 Da · C43H50N8O5S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4297525
Name	Relamorelin
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	44251769
Molecular formula	C43H50N8O5S
Molecular weight	791
InChIKey	KUBPNVYPKPWGRJ-LIVOIKKVSA-N

SMILES: C1CNCCC1C(=O)N[C@H](CC2=CSC3=CC=CC=C32)C(=O)N[C@H](CC4=CNC5=CC=CC=C54)C(=O)N[C@@H](CC6=CC=CC=C6)C(=O)NC7(CCNCC7)C(=O)N

IUPAC name: 4-[[(2S)-2-[[(2R)-2-[[(2R)-3-(1-benzothiophen-3-yl)-2-(piperidine-4-carbonylamino)propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]piperidine-4-carboxamide

Also known as: BIM-28131, BIM28131, Relamorelin, Relamorelina, Relamoreline, RELAMORELIN

Patent coverage: 26 distinct patent families (52 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 7.

Phase distribution

Phase	Trials
PHASE3	5
PHASE2	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03285308	PHASE3	TERMINATED	A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis 01
NCT03383146	PHASE3	TERMINATED	A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 04
NCT03420781	PHASE3	TERMINATED	A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 03
NCT03426345	PHASE3	TERMINATED	Study to Evaluate the Safety and Efficacy of Relamorelin in Participants With Diabetic Gastroparesis Study 02
NCT03786380	PHASE3	TERMINATED	Diabetic Gastroparesis Study 05
NCT02357420	PHASE2	COMPLETED	Safety and Efficacy of Relamorelin Administered to Participants With Vomiting Symptoms and Moderate to Severe Diabetic Gastroparesis
NCT02466711	PHASE1	COMPLETED	Effect of Relamorelin on Satiation, Gastric Volume, Gastric Accommodation and Distal Gastric Function in Healthy Volunteers

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).